Literature DB >> 12372209

[Oral anticoagulation treatment in patients with non-valvular auricular fibrillation].

E Arrojo Arias1, G Mora Navarro, A Abón Santos, M S Araujo Luis, C Capdevila Gallego, M J Gutiérrez Torres.   

Abstract

OBJECTIVES: To evaluate the knowledge, attitudes and difficulties of family doctors in the indication of oral anti-coagulation treatment (OCT) in patients with non-valvular auricular fibrillation (NVAF).
DESIGN: Transversal descriptive study.Setting. Area 11 of Madrid primary care.Participants. 250 doctors by simple randomised sampling. MAIN MEASUREMENTS: After a pilot study at a health centre, mailing of a questionnaire with a subsequent re-mailing. This collected social and personal details, knowledge of the question, attitudes and difficulties.
RESULTS: 157 (62.8%) replied; 91 were women (58.0%); mean age was 39 (SD, 6.0). 97 had reviewed the question recently (61.8%). 110 thought that the anti-aggregation criteria were clear (70.1%; CI, 62.2-77.0%), 107 that the oral anti-coagulation criteria were (68.2%; CI, 60.2-75.2%), 132 that the OCT risks were (84.1%; CI, 77.2-89.2%), and 74 that risk factors of cerebrovascular accident were clear (47.1%; CI, 39.2-55.2%). Initially 96 doctors gave anti-aggregants and referred to cardiology (61.1%; CI, 53.0-68.7%), and 29 began OCT (18.5%; CI, 12.9-25.6%). 134 thought that we avoided initiating OCT (85.3%; CI, 78.6-90.3%), giving as the main reasons the difficulty of monitoring and of requesting further tests, the risks involved and OCT not being up-to-date.
CONCLUSIONS: Most professionals have the criteria for OCT in NVAF clear, although they continue to avoid the initiation of OCT. The majority approach is to give anti-aggregants and refer to Cardiology, given the risk of the therapy and the difficulties involved in monitoring and requesting further tests.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372209      PMCID: PMC7684248          DOI: 10.1016/s0212-6567(02)79029-x

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  28 in total

Review 1.  [Anticoagulant treatment: new aspects of an old therapy].

Authors:  E Vázquez Ruiz de Castroviejo
Journal:  Rev Clin Esp       Date:  1999-02       Impact factor: 1.556

2.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.

Authors:  Daniel E Singer; Robert A Hughes; Daryl R Gress; Mary A Sheehan; Lynn B Oertel; Sue Ward Maraventano; Dyan Ryan Blewett; Bernard Rosner; J Philip Kistler
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

3.  [Prevention of thromboembolic disease in patients with heart disease].

Authors:  G Galindo; R Peiró; A Plana; M A Navarro; J Berdié; J Morató
Journal:  Aten Primaria       Date:  2000-09-30       Impact factor: 1.137

4.  Atrial fibrillation and mortality in an elderly population.

Authors:  F R Lake; K J Cullen; N H de Klerk; M G McCall; D L Rosman
Journal:  Aust N Z J Med       Date:  1989-08

5.  Recent national patterns of warfarin use in atrial fibrillation.

Authors:  R S Stafford; D E Singer
Journal:  Circulation       Date:  1998-04-07       Impact factor: 29.690

6.  [The use of antithrombotic drugs in patients with chronic atrial fibrillation in a local health area].

Authors:  A Aloy-Duch; R Cuenca-Luque; E Rollán-Serrano; J M Casanova-Sandoval
Journal:  Med Clin (Barc)       Date:  1999-04-10       Impact factor: 1.725

7.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

8.  Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project.

Authors:  H J Chang; J R Bell; D B Deroo; J W Kirk; J H Wasson
Journal:  Arch Intern Med       Date:  1990-01

9.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

10.  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

Authors: 
Journal:  Arch Intern Med       Date:  1994-07-11
View more
  1 in total

1.  [The management of atrial fibrillation and characteristics of its current care in outpatients. AFABE observational study].

Authors:  Emmanuel Giménez-García; Josep Lluís Clua-Espuny; Ramón Bosch-Príncep; Carlos López-Pablo; Iñigo Lechuga-Durán; Miquel Gallofré-López; Anna Panisello-Tafalla; Jorgina Lucas-Noll; Maria Lluisa Queralt-Tomas
Journal:  Aten Primaria       Date:  2013-09-14       Impact factor: 1.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.